Condition: Renal Cell Carcinoma · Non Small Cell Lung Cancer · Melanoma · Sponsor: Diwakar Davar
The study will evaluate patient and Health Care Professional- reported preference for Subcutaneous (SC) compared with IV nivolumab administration or similarly for SC compared with IV pembrolizumab.
This description comes directly from the study's public registry record.
Danielle L Bednarz, RN · 4126231191 · bednarzdl@upmc.edu
Amy Rose, RN · 4126478587 · kennaj@upmc.edu
Always discuss trial participation with your own doctor first.
| UPMC Hillman Cancer Center | Pittsburgh, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07223424